BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

Tao Ma; Yan Chen; Zhi-Gang Yi; Yan-Hong Li; Jun Bai; Li-Juan Li; Lian-Sheng Zhang

Genes and Diseases (Nov 2023)

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

Tao Ma,
Yan Chen,
Zhi-Gang Yi,
Yan-Hong Li,
Jun Bai,
Li-Juan Li,
Lian-Sheng Zhang

Affiliations

Tao Ma: Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China; Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, China
Yan Chen: Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China
Zhi-Gang Yi: Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, China
Yan-Hong Li: Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, China
Jun Bai: Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, China
Li-Juan Li: Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, China; Corresponding author. Department of Hematology, Lanzhou University Second Hospital, No. 82 Cuiyingmen Road, Lanzhou, Gansu 730030, China.
Lian-Sheng Zhang: Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, China; Corresponding author. Department of Hematology, Lanzhou University Second Hospital, No. 82 Cuiyingmen Road, Lanzhou, Gansu 730030, China.

Journal volume & issue: Vol. 10, no. 6
pp. 2306 – 2319

Abstract

Read online

The bromodomain and extra-terminal (BET) proteins act as “readers” for lysine acetylation and facilitate the recruitment of transcriptional elongation complexes. BET protein is associated with transcriptional elongation of genes such as c-MYC and BCL-2, and is involved in the regulation of cell cycle and apoptosis. Meanwhile, BET inhibitors (BETi) have regulatory effects on immune checkpoints, immune cells, and cytokine expression. The role of BET proteins and BETi in a variety of tumors has been studied. This paper reviews the recent research progress of BET and BETi in hematologic tumors (mainly leukemia, lymphoma and multiple myeloma) from cellular level studies, animal studies, clinical trials, drug combination, etc. BETi has a promising future in hematologic tumors, and future research directions may focus on the combination with other drugs to improve the efficacy.

Published in Genes and Diseases

ISSN: 2352-3042 (Online)
Publisher: KeAi Communications Co., Ltd.
Country of publisher: China
LCC subjects: Medicine: Medicine (General); Science: Biology (General): Genetics
Website: https://www.keaipublishing.com/en/journals/genes-and-diseases/

About the journal

Abstract

Keywords